Clinical Trial Update: Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pharmacokinetic interactions between zanubrutinib and moderate/strong CYP3A inhibitors in participants with B-cell malignancies. Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: B-cell Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2023-11-27